

Particular Patterns of the Influence of the Physiology of Normal Pregnancy on the Pharmacokinetics of Drugs in the Liver

ABSTRACT

Pregnant women are the most "untouchable" group of people in relation to pharmacological research due to ethical and legal aspects, as well as concerns for the health and integrity of the fetus. And that is why pregnant women practically do not participate in clinical, pharmacodynamic, or pharmacokinetic testing. The mechanisms of teratogenesis are unpredictable, and in this case mutations can occur regardless of the duration of pregnancy and at any level. In women during pregnancy, the activity of liver enzyme systems involved in drug metabolism changes completely, which affects their clearance. This should be taken into account when selecting drugs and dosages for the treatment of various diseases. Our study showed that during pregnancy, a significant decrease in the intrinsic hepatic clearance of the CYP1A2 substrate is enhanced by a decrease in the binding of theophylline to plasma proteins and an increase in the glomerular filtration rate.

Key words: liver enzymes, pregnancy, caffeine, proguanil, lamotrigine, phenytoin, methadone.

1. INTRODUCTION

1.1 RELEVANCE

Pregnant women are the most "untouchable" group of people in relation to pharmacological research due to ethical and legal aspects, as well as concerns for the health and integrity of the fetus. And that is why pregnant women practically do not participate in clinical, pharmacodynamic, or pharmacokinetic testing. This leads to the fact that all responsibility for assessing the risk and benefit of a particular drug in a particular clinical situation falls solely on the attending doctor. After all, reproductive scientific research on animals does not always allow us to predict the results in humans. The most dangerous and fraught reactions are drug-induced fetal malformations. The mechanisms of teratogenesis are unpredictable, and in this case mutations can occur regardless of the duration of pregnancy and at any level. In addition to this problem, women in the position are very often left without the necessary therapy, thus trying to mitigate all the risks associated with the use of medicines and avoid unnecessary effects on the fetus, sometimes even ignoring the patient's condition [1, 2]. Or another perspective: often doctors do not adjust the dosage and frequency of taking the drug and prescribe a standard scheme for adults, without taking into account the physiological changes in the body of a pregnant woman [3,4].

There are two important reasons to study individual medications and drug therapy during pregnancy. Firstly, the change in reproductive age. The realities of life are such that currently women from 10 to about 50 years old are considered to be of reproductive age, and even elderly women can become pregnant with the help of in vitro fertilization and donor eggs [5]. This expansion of the boundaries of pregnancy increases the number of women who may require therapy to treat diseases that occur during pregnancy and continue after its onset [6,7]

Secondly, these are physiological transformations during the gestation period. Adaptive metabolic settings can affect the pharmacokinetics of drugs, changing their peak concentration and the time it takes to reach it by reducing the binding of the compound to plasma proteins and increasing the volume of distribution. In addition, changes in renal and (or) hepatic clearance may occur [8]. When extrapolating pharmacokinetic data obtained from studies involving mostly non-pregnant women, physiological changes occurring during pregnancy are not taken into account for pregnant women. This may affect the effectiveness of the drug and, ultimately, the overall outcome of pregnancy [4,9].

The purpose of the study: to conduct a review analysis of the literature on pharmacokinetics of drugs on specific examples.

2. RESULTS AND DISCUSSION

During pregnancy, women completely change the activity of liver enzyme systems involved in drug metabolism, which affects their clearance. This should be taken into account when selecting drugs and dosages for the treatment of various diseases [10,11].

In pregnant women, the activity of liver enzymes involved in the metabolism of pharmacological drugs completely changes, which affects their clearance [12]. There is also an almost hundredfold increase in the level of estradiol compared to the initial concentration in non-pregnant women [13]. The hormone progesterone, responsible for maintaining the normal course of processes during pregnancy, also increases sharply from 30-40 ng/ml (in the luteal phase) to 100-200 ng/ml. These changes in the level of estrogen and progesterone, as well as other placental hormones and hormonal metabolites, can affect the enzymatic activity of the liver [14-16].

CYP3A4 substrates: in numerous studies involving women in the position, it has been proven that the clearance of CYP3A4 substrate drugs increases during pregnancy. Due to the fact that midazolam is eliminated exclusively through CYP3A4 metabolism [17], its clearance in the ratio of serum metabolites in concentration, 1-hydroxymidazolam/midazolam are recognized as markers of CYP3A4 activity [18]. In full-term pregnancy, the clearance of midazolam is 2.9 times greater than in non-pregnant women. The metabolic coefficient of cortisol, a non-specific marker of CYP3A4 activity, in pregnant women shortly before childbirth was increased compared to the same women one week and three months after childbirth [19]. In women in the third trimester of pregnancy, the clearance of nifedipine was increased by 4 times compared to the historical control. Methadone, which is used in the treatment of heroin addiction during pregnancy, is also a substrate of CYP3A4. In a study of the pharmacokinetics of methadone during pregnancy in the second trimester, its clearance doubled, but decreased slightly in the third. This change is both statistically and clinically very significant, since a decrease in the level of methadone in plasma can lead to the development of withdrawal syndrome (if the dosage is not adjusted). In the study of metronidazole with delayed release, which is mainly metabolized by CYP3A4, it was found that in the second and early third trimester, the total clearance of

the drug in pregnant women with oral administration was 27% higher than in non-pregnant women. The average maximum concentration of metronidazole was approximately 25% lower during pregnancy, and this difference in the values of the area under the concentration-time curve (AUC) in pregnant women compared with non-pregnant women was approaching statistically significant [17].

The factor stimulating the induction of CYP3A4 during pregnancy is still unknown. However, both estradiol, estran and (as well as natural progestins: progesterone, pregnenolone, 17-hydroxyprogesterone and 5 β -pregnan-3,20-dione), and have been proven to activate the nuclear pregnan X receptor (pxr of the pregnan X receptor) [20,21].

CYP1A2 substrates: the clearance of caffeine, a CYP1A2 substrate, decreases by two by the middle of pregnancy, and by the third trimester - by three times compared with the postpartum period [22,23]. Although theophylline's own hepatic clearance decreases during pregnancy, its hepatic clearance changes slightly due to a decrease in the binding of theophylline to various plasma proteins [24].

As a result of compensating changes in hepatic and renal clearance, which were discussed above, in the third trimester of pregnancy in general, the clearance of theophylline remains unchanged.

CYP2D6 substrates: the activity of CYP2D6, which is known to be determined genetically, during pregnancy, oddly enough, increased in homozygous and heterozygous "fast metabolizers". However, the activity of this enzyme decreased in homozygotes with slow metabolism [25].

CYP2C9 substrates: the hepatic clearance of a limited metabolized phenytoin drug, which is mainly a CYP2C9 substrate, increases during pregnancy, which leads to a corresponding reduction in its total concentration in blood plasma [26]. This is largely due to a decrease in its binding to proteins, which is precisely confirmed for phenytoin, since the concentration of free substance in blood plasma has been shown to remain relatively constant until late pregnancy, when the internal clearance of this drug increases.

CYP2C19 substrates: The conversion of the antimalarial drug proguanil into its active metabolite cycloguanil occurs with the participation of CYP2C19. The metabolic coefficient of proguanil to cycloguanil has been found to increase by about 60% during pregnancy [27]. In a population study, CYP2C19-dependent clearance decreased by 50% [28].

NAT2 substrates: using caffeine to study the transformation of liver enzymatic activity during pregnancy, both pregnant and non-pregnant women with epilepsy were examined. It was found that the activity of N-acetyltransferase (NAT - N-acetyltransferase) decreases during pregnancy. In some cases, caffeine was used to show that the normal activity of N-acetyltransferase in healthy women decreases during pregnancy [29, 30].

Glucuronidation process: the anticonvulsant and normotimic drug lamotrigine is metabolized by glucuronidation. It has been studied that its clearance [29] increases by more than 50% during pregnancy, which requires dosage adjustment. After childbirth, the clearance of lamotrigine quickly returns to the pre-pregnancy level, so the dose should be reduced during the first two weeks of the postpartum period [31, 32].

The thyroid gland increases slightly during pregnancy. In the first half of pregnancy, its hyperfunction is noted, in connection with which the main metabolism changes. At the same

time, an increase in total plasma T4 is associated with an increase in thyroxine-binding globulin, and free T4 remains within the normal range. Thus, during physiological pregnancy, we observe changes in all types of metabolism. During pregnancy, a decrease in the total concentration of protein in the blood plasma is apparently due to both partial dilutions, due to fluid retention in the body, and a decrease in the concentration of albumin. The decrease in the level of albumin is mainly due to the increased use of it for biosynthetic processes. However, a change in the permeability of vascular membranes and the redistribution of fluids and protein in the extracellular sector, hemodynamic disorders cannot be excluded as an influencing factor. A change in the hormonal background leads to an increase in the content of many specific carrier proteins, which is accompanied by a proportional increase in the content of the compound associated with it.

Progesterone is one of the main hormones in a woman's body, which ensures a regular menstrual cycle, plays an important role in the processes of pregnancy onset and preservation. The actions of this hormone: decidual transformations of the endometrium and its preparation for implantation, increased vascularization of the myometrium, stimulation of growth and development of mammary glands [34].

3. CONCLUSION

Betamethasone also undergoes glucuronidation in the liver, and, as it has been shown, its clearance in pregnant women is higher than in non-pregnant women. It was also found that in a two-pregnancy, the clearance of betamethasone is higher and, accordingly, its half-life is shorter than in a single pregnancy. This is believed to be caused by the increased metabolism of betamethasone with the participation of an additional fetoplacental system in a two-pregnancy pregnancy. A shorter half-life and a higher clearance can also explain the decrease in the effectiveness of betamethasone in reducing the incidence of respiratory distress syndrome in a two-pregnancy pregnancy.

Acknowledgment

The work was carried out with support of the Center for Collective Use of North Caucasus Federal University

REFERENCES

1. Brucker MC, King TL. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule. *J Midwifery Womens Health*. 2017 May;62(3):308-316. doi: 10.1111/jmwh.12611. Epub 2017 May 29.
2. Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. *Semin Perinatol*. 2015 Nov;39(7):512-9. doi: 10.1053/j.semperi.2015.08.003.
3. Patil AS, Sheng J, Dotters-Katz SK, Schmoll MS, Onslow M, Pierson RC. Fundamentals of Clinical Pharmacology With Application for Pregnant Women. *J Midwifery Womens Health*. 2017 May;62(3):298-307. doi: 10.1111/jmwh.12621. Epub 2017 May 12.
4. Bledzhyants G. A., Mishvelov A. E., Nuzhnaya K.V., Anfinogenova O.I., Isakova J. A., Melkonyan R. S., et al. The Effectiveness of the Medical Decision-Making Support System "Electronic Clinical Pharmacologist" in the Management of Patients Therapeutic Profile, *Pharmacophore*, 2019; 10(2), 76-81
5. Malm H, Eilfolk M. Which drugs can be used during pregnancy? *Duodecim*. 2016;132(19):1781-9.
6. Niebyl JR. Drug therapy during pregnancy. *Curr Opin Obstet Gynecol*. 1992 Feb;4(1):43-7.

7. Joshi MD. Drug delivery during pregnancy: how can nanomedicine be used? *Ther Deliv.* 2017 Dec;8(12):1023-1025. doi: 10.4155/tde-2017-0084.
8. Trad PV. Adaptation to developmental transformations during the various phases of motherhood. *J Am Acad Psychoanal.* 1991 Fall;19(3):403-21. doi: 10.1521/jaap.1.1991.19.3.403
9. Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, Menéndez C, Bardají A, Chaccour C. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. *Lancet Glob Health.* 2020 Jan;8(1):e92-e100. doi: 10.1016/S2214-109X(19)30453-X.
10. Raevskaya A I, Belyalova A A, Shevchenko P P, Karpov S M, Mishvelov A E, Simonov A N, Povetkin S.N. et al. Cognitive Impairments in A Range of Somatic Diseases Diagnostics, Modern Approach to Therapy . *Pharmacophore* 2020;11(1):136-41.
11. Rzhepakovsky I., Siddiqui S.A., Avanesyan S., Benlidayi M., Dhingra K., Dolgalev A., Erukashvily N., Fritsch T., Heinz V., Kochergin S., Nagdalian A., Sizonenko M., Timchenko L., Vukovic M., Piskov S., Grimm W-D. Anti- arthritic effect of chicken embryo tissue hydrolyzate against adjuvant arthritis in rats (X- ray microtomographic and histopathological analysis). *Food Science & Nutrition* 2021, 00:1-22. <https://doi.org/10.1002/fsn3.2529>.
12. Kh. Kh. Ilyasov, E.L. Demchenkov, A.S. Chernyshkov, I.A. Rodin, S.V. Pushkin, S.N. Povetkin, and et al. "Features of the Phytopharmacological Preparations in the Metaphylaxis of Urolithiasis", *Pharmacophore*, 2020; 11(5), 66-71
13. Deng L, Chen X, Ye DS, Chen SL. [Effect of serum estradiol level before progesterone administration on pregnancy outcomes of frozen-thawed embryo transfer cycles]. *Nan Fang Yi Ke Da Xue Xue Bao.* 2018 May 20;38(5):601-605. Chinese. doi: 10.3969/j.issn.1673-4254.2018.05.16.
14. Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. *CNS Spectr.* 2015 Feb;20(1):48-59. doi: 10.1017/S1092852914000480. Epub 2014 Sep 29.
15. Marek B, Kot T, Buntner B. Ocena przydatności oznaczeń estrogenów i progesteronu w ślinie w przebiegu ciąży [Usefulness of measuring the levels of estrogens and progesterone in the saliva during pregnancy]. *Ginekol Pol.* 1989 May;60(5):291-4. Polish.
16. Tatamov, A. A., Boraeva, T. T., Revazova, A. B., Alibegova, A. S., Dzhanelaliev, K. M., Tetueva, A. R., Yakubova, L. A., Tsoma, M. V., Mishvelov, A. E. and Povetkin, S. N. "Application of 3D Technologies in Surgery on the Example of Liver Echinococcosis", *Journal of Pharmaceutical Research International*, 2021; 33(40A), pp. 256-261. doi: 10.9734/jpri/2021/v33i40A32242.
17. Abduljalil K, Pansari A, Jamei M. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. *J Pharmacokinet Pharmacodyn.* 2020 Aug;47(4):361-383. doi: 10.1007/s10928-020-09711-2. Epub 2020 Aug 25.
18. Khatri R, Kulick N, Rementer RJB, Fallon JK, Sykes C, Schauer AP, Malinen MM, Mosedale M, Watkins PB, Kashuba ADM, Boggess KA, Smith PC, Brouwer KLR, Lee CR. Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression. *J Pharm Sci.* 2021 Jan;110(1):412-421. doi: 10.1016/j.xphs.2020.09.013. Epub 2020 Sep 12.
19. Mathias AA, Maggio-Price L, Lai Y, Gupta A, Unadkat JD. Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein. *J Pharmacol Exp Ther.* 2006 Mar;316(3):1202-9. doi: 10.1124/jpet.105.095406. Epub 2005 Nov 17.
20. Xiang E, Guo Q, Dai YG, Sun XX, Liu J, Fan CP, Wang YQ, Qiu SK, Wang H, Guo Y. Female-specific activation of pregnane X receptor mediates sex difference in fetal

- hepatotoxicity by prenatal monocrotaline exposure. *Toxicol Appl Pharmacol.* 2020 Nov 1;406:115137. doi: 10.1016/j.taap.2020.115137. Epub 2020 Jul 17.
21. Hagedorn KA, Cooke CL, Falck JR, Mitchell BF, Davidge ST. Regulation of vascular tone during pregnancy: a novel role for the pregnane X receptor. *Hypertension.* 2007 Feb;49(2):328-33. doi: 10.1161/01.HYP.0000253478.51950.27. Epub 2006 Dec 11.
 22. CARE Study Group. Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study. *BMJ.* 2008 Nov 3;337:a2332. doi: 10.1136/bmj.a2332. Erratum in: *BMJ.* 2010;340. doi: 10.1136/bmj.c2331.
 23. Osipchuk GV, Povetkin SN, Ashotovich A, Nagdalian IA, Rodin MI, Vladimirovna I, et al. The issue of therapy postpartum endometritis in sows using environmentally friendly remedies. *Pharmacophore.* 2019;10(2):82-4..
 24. Connelly TJ, Ruo TI, Frederiksen MC, Atkinson AJ Jr. Characterization of theophylline binding to serum proteins in pregnant and nonpregnant women. *Clin Pharmacol Ther.* 1990 Jan;47(1):68-72. doi: 10.1038/clpt.1990.10.
 25. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. *Clin Pharmacol Ther.* 1997 Oct;62(4):400-7. doi: 10.1016/S0009-9236(97)90118-1.
 26. Shah M, Xu M, Shah P, Wang X, Clark SM, Costantine M, West HA, Nanovskaya TN, Ahmed MS, Abdel-Rahman SZ, Venkataramanan R, Caritis SN, Hankins GDV, Rytting E. Effect of CYP2C9 Polymorphisms on the Pharmacokinetics of Indomethacin During Pregnancy. *Eur J Drug Metab Pharmacokinet.* 2019 Feb;44(1):83-89. doi: 10.1007/s13318-018-0505-7.
 27. Hippman C, Slomp C, Morris E, Batallones R, Inglis A, Carrion P, Brain U, Higginson M, Wright GEB, Balneaves LG, Ryan D, Nislow C, Ross CJD, Gaedigk A, Oberlander TF, Austin J. A cross-sectional study of the relationship between CYP2D6 and CYP2C19 variations and depression symptoms, for women taking SSRIs during pregnancy. *Arch Womens Ment Health.* 2021 Jul 7. doi: 10.1007/s00737-021-01149-w.
 28. Fokina VM, Xu M, Rytting E, Abdel-Rahman SZ, West H, Oncken C, Clark SM, Ahmed MS, Hankins GD, Nanovskaya TN. Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy. *Drug Metab Dispos.* 2016 Nov;44(11):1832-1838. doi: 10.1124/dmd.116.071530. Epub 2016 Aug 15.
 29. Schmidt RJ, Romitti PA, Burns TL, Murray JC, Browne ML, Druschel CM, Olney RS; National Birth Defects Prevention Study. Caffeine, selected metabolic gene variants, and risk for neural tube defects. *Birth Defects Res A Clin Mol Teratol.* 2010 Jul;88(7):560-9. doi: 10.1002/bdra.20681.
 30. Maslova, A. Y., Bazaeva, K. L., Abdullaeva, Z. A., Khazamova, S. O., Zeusheva, K. A., Grechkina, T. A., Semkina, E. N., Abramov, M. A., Mishvelov, A. E. and Povetkin, S. N. "Astrocytes and their Phenomenal Possibilities in the Treatment of Various Neurodegenerative Disorders: An Overview", *Journal of Pharmaceutical Research International*, 2021; 33(33A), 60-68. doi: 10.9734/jpri/2021/v33i33A31772.
 31. Chen S, Yueh MF, Evans RM, Tukey RH. Pregnane-x-receptor controls hepatic glucuronidation during pregnancy and neonatal development in humanized UGT1 mice. *Hepatology.* 2012 Aug;56(2):658-67. doi: 10.1002/hep.25671. Epub 2012 Jun 11.
 32. Tran H, Robb AS. SSRI use during pregnancy. *Semin Perinatol.* 2015 Nov;39(7):545-7. doi: 10.1053/j.semperi.2015.08.010. Epub 2015 Oct 1.
 33. Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. *Am J Gastroenterol.* 2016 Feb;111(2):176-94; quiz 196. doi: 10.1038/ajg.2015.430. Epub 2016 Feb 2. Erratum in: *Am J Gastroenterol.* 2016 Nov;111(11):1668.
 34. Makatsaria A.D., Bitsadze V.O., Baimuradova S.M. Application natural progesterone in obstetric and gynecological practice. Moscow. 2009 .44 p.